spacer
home > epc > autumn 2008 > intellectual property
PUBLICATIONS
European Pharmaceutical Contractor

Intellectual Property

The continued growth and prosperity of the pharmaceutical industry relies on the exploitation of existing products and innovation. The industry faces, in particular, difficulties of competition (both lawful and unlawful), heavy regulation, consumer interest and public policy. It is vital for a pharmaceutical company to develop a strategy that protects its position in the industry, allows it to expand, maximises its investment and continues innovation whilst dealing with the competitive regulated market. Intellectual property (IP) rights are critical tools which assist pharmaceutical companies in crossing this minefield.

THE NEED FOR AN IP STRATEGY

In an industry where the cost of research and development equates to 33.3 per cent of the revenue from sales, it is crucial for businesses to protect the investment incurred in carrying out that R&D (1). IP can be a pharmaceutical company’s most valuable resource. Mismanagement and failure to protect IP can lead to serious damage to the value of a business. The right IP strategy can maximise the return on the investment and assist with sustainability and commercialisation.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Colin Bell is a Lawyer in the Commercial and Intellectual Property department at Brabners Chaffe Street LLP, Solicitors, based in their Liverpool office. Colin has extensive experience in all aspects of contentious and non-contentious IP and advises on the identification, protection, exploitation and enforcement of IP, which includes filing and prosecuting trade mark and design applications. He is also part of the biotechnology multidisciplinary team at Brabners Chaffe Street LLP.
spacer
Colin Bell
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement